Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.

Biotechnology

Foghorn Therapeutics

Adrian Gottschalk

Kristian F. Humer

Anna Rivkin

Alfonso Quintás-Cardama

Andrew Germain

Dan Dinu

Saurabh Sewak

Karin Hellsvik

Gromek Smolen

Danette L. Daniels

Steven Bellon

Michael Lacascia

Samuel Agresta

Murphy Hentemann

Carlos Costa

Chong-Hui Gu

Marina Nelen

Kevin Wilson

Ben Strain

Directors and Advisors

Leadership Team

Vice Presidents

Teams at Foghorn Therapeutics

Directors and Advisors

Leadership Team

Vice Presidents